Main Sequence backs dementia biotech Kinoxis in US$5.99M round
What's the deal? Kinoxis Therapeutics, an Australian biotech tackling pain and agitation in dementia patients, has raised US$5.99M (roughly $6.5 million) in a late-stage venture round. CSIRODealroom has a profile for this one. Try Dealroom →-backed venture capital firm Main SequenceDealroom has a profile for this one. Try Dealroom → contributed to the round, which also included a US$1.62M grant.
What's the endgame? Kinoxis is developing treatments for pain and for agitation in people living with dementia — conditions with limited existing options. The fresh capital advances that work.
Why now? The round was announced in September 2026, pairing private venture money with grant funding to push the startup's programs forward.
The signal: At about $6.5 million, the raise sits in the lower band of comparable biotech rounds — modest capital paired with non-dilutive grant support. For an early-stage therapeutics company, that mix reflects how Australian deep-tech ventures stretch investor dollars alongside public backing to fund long clinical timelines.
Read more: startupdaily.net
Image credit: Direct Media
